Evidence map›Paper›PMID 34786866›Full record

ArticleCancer medicine2021

Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India.

Sumeet P Mirgh, Anant Gokarn, Akhil Rajendra, Ashwini More, Sujit Kamtalwar, Kritika S Katti, Anuj Singh, Vasu Babu Goli, Rahul Ravind, Ravikrishna Madala and 21 more

Abstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Sumeet P MirghBMT Unit, Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.ORCID 0000-0003-0642-2207
Anant GokarnBMT Unit, Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Akhil RajendraHomi Bhabha National Institute, Mumbai, India.
Ashwini MoreDepartment of Medicine, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Sujit KamtalwarDepartment of Medicine, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Kritika S KattiDepartment of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Anuj SinghDepartment of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Vasu Babu GoliDepartment of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Rahul RavindDepartment of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Ravikrishna MadalaDepartment of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Sangeeta KakotiDepartment of Radiation Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Priyamvada MaitreDepartment of Radiation Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Sachin PunatarBMT Unit, Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Akanksha ChichraBMT Unit, Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Amar PatilDepartment of Medicine, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Bhakti TrivediHomi Bhabha National Institute, Mumbai, India.
Amit JoshiHomi Bhabha National Institute, Mumbai, India.
Nikhil PatkarHomi Bhabha National Institute, Mumbai, India.
Prashant TembhareHomi Bhabha National Institute, Mumbai, India.
Twinkle KhankaHomi Bhabha National Institute, Mumbai, India.
Sweta RajpalHomi Bhabha National Institute, Mumbai, India.
Gaurav ChatterjeeHomi Bhabha National Institute, Mumbai, India.
Sadhana KannanDepartment of Biostatistics, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
P G SubramanianHomi Bhabha National Institute, Mumbai, India.
Vedang MurthyDepartment of Radiation Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.
Nitin ShettyHomi Bhabha National Institute, Mumbai, India.
Preeti ChavanHomi Bhabha National Institute, Mumbai, India.
Vivek BhatHomi Bhabha National Institute, Mumbai, India.
Sudhir NairHomi Bhabha National Institute, Mumbai, India.
Navin KhattryBMT Unit, Department of Medical Oncology, ACTREC - Tata Memorial Centre, Navi Mumbai, India.ORCID 0000-0001-5708-6472
Sudeep GuptaHomi Bhabha National Institute, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is paucity of data regarding clinical characteristics, laboratory parameters and outcomes of coronavirus disease (COVID-19) in cancer versus non-cancer patients, particularly from India. MATERIALS AND

methodsThis was an observational, single-centre, retrospective analysis of patients with laboratory-confirmed COVID-19 hospitalised in our institution between 22 May 2020 and 1 December 2020. We compared baseline clinical characteristics, laboratory parameters and outcomes of COVID-19 (overall mortality, time to discharge) between cancer and non-cancer patients.

resultsA total of 200 COVID-19 infection episodes were analysed of which 109 (54.5%) were patients with cancer and 91 (45.5%) were patients without cancer. The median age was 43 (interquartile range [IQR]:32-57), 51 (IQR: 33-62) and 38 (IQR: 31.5-49.3) years; of whole cohort, cancer and non-cancer patients, respectively. Comparison of outcomes showed that oxygen requirement (31.2% [95% CI: 22.6-40.7] vs. 17.6% [95% CI: 10.4-26.9]; p = 0.03), median time to discharge (11 days [IQR: 6.75-16] vs. 6 days [IQR: 3-9.75]; p < 0.001) and mortality (10.0% [95% CI: 5.2-17.3] vs. 1.1% [95% CI: 0.03-5.9]; p = 0.017) were significantly higher in patients with cancer. In univariable analysis, factors associated with higher mortality in the whole cohort included diagnosis of cancer (10.1% vs. 1.1%; p = 0.027; odds ratio [OR]: 7.04), age ≥60 (17.4% vs. 2.6%; p = 0.001; OR: 7.38), oxygen requirement (22% vs. 0.6%; p < 0.001; OR: 29.01), chest infiltrates (19.2% vs. 1.4%; p < 0.001; OR: 22.65), baseline absolute lymphocyte count <1 × 10

conclusionCancer patients with COVID-19 have higher mortality and require longer hospital stay. High procalcitonin levels and oxygen requirement during admission are other factors that affect outcomes adversely.

Indexed as

AdultCOVID-19FemaleHospitalizationHumansIndiaMaleMiddle AgedNeoplasmsRetrospective StudiesRisk FactorsTertiary Care CenterscancerCOVID-19non-canceroutcomes

Identifiers

PMID34786866
PMCPMC8646792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.